GTx, Inc. Share Price Nasdaq
Equities
US40052B2079
Biotechnology & Medical Research
Sales 2024 * | 878K 73.11M | Sales 2025 * | 675K 56.19M | Capitalization | 27.85M 2.32B |
---|---|---|---|---|---|
Net income 2024 * | -35M -2.91B | Net income 2025 * | -48M -4B | EV / Sales 2024 * | 31.7 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 41.3 x |
P/E ratio 2024 * |
-0.79
x | P/E ratio 2025 * |
-1.11
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.7% |
Latest transcript on GTx, Inc.
Managers | Title | Age | Since |
---|---|---|---|
James Breitmeyer
FOU | Founder | 70 | 01/97/01 |
Richard Vincent
DFI | Director of Finance/CFO | 61 | 01/17/01 |
Salim Yazji
CTO | Chief Tech/Sci/R&D Officer | 55 | 17/21/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Hale
FOU | Founder | 75 | 01/97/01 |
Dan Kisner
BRD | Director/Board Member | 77 | 07/19/07 |
Rosemary Mazanet
BRD | Director/Board Member | 68 | 27/21/27 |
1st Jan change | Capi. | |
---|---|---|
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+40.01% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |